NCT03417544 2025-04-02Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BCDana-Farber Cancer InstitutePhase 2 Active not recruiting19 enrolled 26 charts
NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts